Allergy immune therapy treats allergic reactions due to stringent insect hypersensitivity, conjunctivitis, and asthma. The therapy has daily administration of prescribed doses. In several countries a new type of therapy, sublingual immunotherapies has been launched, which makes the key players bank upon this opportunity.
Allergy can be explained as a response of the immune system to foreign elements called allergens. These are although not harmful for the body, but show an external reaction in the form of itchy rashes, red eyes, cold, shortness of breath, swelling, and sneezing, etc. Some of the common allergens include certain food items, pet dander, pollen, dust, certain insects, metals, etc. The immunotherapy treatment is adopted to prevent from any further emergency situations and complications. Allergy immunotherapy is desensitization or hypo-sensitization medical treatment administered for allergies. Measured doses of anti-allergens are prescribed to the person with allergy, making their system respond less sensitively to the foreign substance. This is done by the function of antibody, which results in the lessening of inflammation.
The rising number of people suffering from various allergies is likely to be the key factor boosting the demand in the global allergy immunotherapy market in the upcoming years. Changing climatic conditions and altered lifestyle patterns are some additional factors uplifting the growth in the global market. Resultantly, there has been a significant increase in awareness about allergy immunotherapy. Regular health check-ups are expected to fuel the global business for the same in the forecast period.
Generally, people with a family history of allergies are more likely to develop the allergies as well. In such cases, people need to be precautious about their situation and should be careful not to expose themselves to the allergic elements as much as possible. Sometimes food allergies can turn out to be life-threatening. Thus, the awareness among the people about the treatment and allergy immunotherapy is foreseen to help curb the situation to a large extent, spiking the market growth as well.
The global allergy immunotherapy market is broadly classified into treatment type, allergy type, distribution channel, and region. The treatment type segment is bifurcated into SLIT and SCIT. Based on allergy type, the market is divided into asthma, allergic rhinitis, venom allergy, food allergy, and others. The distribution channel is fragmented into retail pharmacies & drug stores, online pharmacies, and hospital pharmacies.
Geographically, Europe is estimated to lead the global allergy immunotherapy market within the forecast period. This is credited to the huge population base and numerous people suffering from various allergies. The region is trailed by North America with the US as the key contributing country in the growth of the regional market.
The key players leading in the global allergy immunotherapy market include Aimmune Therapeutics, Abello, Stallergenes Greer, Biomay, Allergy Therapeutics, Merck, Circassia, DBV Technologies, HAL Allergy, Anergis, etc. To cite, ALK Abello in April 2020 got its approval for ITULATEK, a once-a-day sublingual tablet, from Health Canada. The tablet is produced specifically to treat allergies from tree pollen.